Clinical TrialJul 21, 2026, 04:33 PM
Acrivon's ACR-2316 Shows PRs in Multiple AP3-Predicted Tumor Types
AI Summary
Acrivon Therapeutics announced it will present mechanistic data and early clinical responses for its WEE1/PKMYT1 inhibitor, ACR-2316, at the AACR D3 Conference. The presentations will highlight partial responses (PRs) and durable clinical benefit in AP3-predicted tumor types, including small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), and adenosarcoma NSCLC (adNSCLC), as well as endometrial cancer. ACR-2316 has also demonstrated a favorable tolerability profile, primarily limited to transient neutropenia, underscoring the effectiveness of the company's AP3-guided drug design.
Key Highlights
- ACR-2316, a WEE1/PKMYT1 inhibitor, shows early clinical responses.
- Partial responses (PRs) observed in SCLC, sqNSCLC, and adNSCLC.
- ACR-2316 also showed PRs in endometrial cancer, AP3-predicted tumor types.
- Favorable tolerability profile with transient, mechanism-based neutropenia.
- Presentations on ACR-2316 and AP3 platform at AACR D3 Conference.
- ACR-2316 is in a Phase 1/2 clinical study, advancing to dose expansion.
- AP3 platform guided ACR-2316 design for potent single agent activity.
Price Impact
More from ACRV